Domain Therapeutics is granted European and US patent for biosensors assessing GPCR trafficking
Domain Therapeutics announced that it has been granted a patent in the US and in Europe covering a novel family of biosensors.
The patent, entitled ‘Biosensors for monitoring biomolecule localization and trafficking in cells’, was initially filed by Prof. Michel Bouvier and his team and is part of the technology licensed to Domain Therapeutics by the Universities of Montreal and McGill, Canada.
The trafficking biosensors covered by the patent are used by Domain Therapeutics to monitor the intracellular trafficking and recycling of GPCRs. They belong to a new generation of sensors and complete the panel of 63 unique biosensors constituting the bioSens-All™ technology. These biosensors are designed to profile G Proteins, including G12 and G13, Beta-arrestins, second messengers and receptor trafficking.
“This granted patent illustrates our strategy to stay at the forefront of innovation in technologies for challenging GPCRs. It will help the company address unmet medical needs with drugs acting through brand new mechanisms of action,” said Pascal Neuville, CEO, Domain Therapeutics. “In collaboration with Prof. Michel Bouvier, we have already taken advantage of this unique technology to launch a chaperone program targeting a mutated GPCR with impaired trafficking.”
Other news from the department research and development
These products might interest you
Octet R2 / Octet R4 / Octet R8 by Sartorius
Full power on 2, 4 or 8 channels: Label-free and GxP-compliant analysis of molecular interactions
Innovative label-free real-time protein quantification, binding kinetics and rapid screenings
Octet RH16 and RH96 by Sartorius
Efficient protein analysis for process optimisation and manufacturing control in high-throughput
Label-free protein quantification and characterization of protein-protein interactions
Octet SF3 by Sartorius
Surface Plasmon Resonance (SPR) using Single Dynamic Injections for Kinetics and Affinities
Curvature is Key - Adding a ‘Third Dimension’ to the Binding Curve
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.